COCP

Cocrystal Pharma Inc

1.03

Nov 10 • 3:59 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Nano NASD

Peers: AVIR ENTA TRAW ALGS NNVC ASMB ABUS IVVD ACXP SNGX

| Held by: VTI VXF

Scroll to Statements

Index	-
Market Cap	19.84M
Enterprise Value	18.94M
Income	-9.94M
Sales	0.33M
Book/sh	0.08
Cash/sh	0.12
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	10
IPO	Apr 01, 2008

P/E	-
Forward P/E	-
PEG	-
P/S	60.12
P/B	13.60
P/C	8.86
P/FCF	-
EV/EBITDA	-
EV/Sales	57.39
Quick Ratio	1.24
Current Ratio	1.24
Debt/Eq	1.29
LT Debt/Eq	0.95
Option/Short	No / Yes

EPS (ttm)	-0.76
EPS next Y	-0.47
EPS next Q	-0.18
EPS this Y	7.05%
EPS next Y	34.48%
EPS next 5Y	6.87%
EPS past 3/5Y	45.26% 17.90%
Sales past 3/5Y	- -
EPS Y/Y TTM	38.55%
Sales Y/Y TTM	-
EPS Q/Q	-13.61%
Sales Q/Q	-
Earnings	Aug 17
EPS/Sales Surpr.	-39.39% -

Insider Own	33.53%
Insider Trans	1.33%
Inst Own	5.97%
Inst Trans	15.22%
ROA	-151.10%
ROE	-311.68%
ROIC	-488.83%
Gross Margin	37.27%
Oper. Margin	-3063.64%
Profit Margin	-3011.52%
SMA20	2.91%
SMA50	-5.44%
SMA200	-6.46%
Trades

Shs Outstand	13.79M
Shs Float	12.81M
Short Float	1.42%
Short Ratio	3.89
Short Interest	0.18M
52W High	2.03 -49.26%
52W Low	0.76 35.53%
Volatility	8.62% 7.25%
ATR (14)	0.07
RSI (14)	49.19
Beta	1.60
Rel Volume	0.00
Avg Volume	46.60K
Volume	0

Perf Week	-3.74%
Perf Month	-2.83%
Perf Quarter	-8.04%
Perf Half Y	-21.37%
Perf YTD	5.21%
Perf Year	-2.83%
Perf 3Y	-45.79%
Perf 5Y	-90.56%
Perf 10Y	-99.42%
Recom	1.00
Target Price	7.00
Prev Close	1.03
Price	1.03
Change %	0.00%

Consensus

Strong Buy

Avg. Price Target

$7.00

Implied Upside

+579.6%

Analysts1incl. previous ratings

Rating Distribution1 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Jul 08, 2020	Initiated	HH.C. Wainwright	Buy	$5	+385.4%

Sep-18-26 09:48AM	A norovirus breakthrough?; another womens healthtech haul (Pharma Voice) +6.14%
Sep-15-26 08:56AM	Cocrystal Pharmas new CEO hopes to crack the norovirus code (Pharma Voice)
Sep-09-26 07:00AM	Cocrystal Pharma Announces Last Subject Dosed in Phase 1b Human Challenge Study Evaluating CDI-988 for Norovirus Prevention and Treatment (GlobeNewswire) +5.08%
Aug-31-26 11:39AM	Cocrystal Pharma: The Strategic Reset Investors May Be Missing (Exec Edge) +5.45%
Aug-17-26 11:17AM	Cocrystal Pharma Appoints Carol Brosgart, MD to its Board of Directors (GlobeNewswire)
07:00AM	Loading…
Aug-03-26 07:00AM	Cocrystal Pharma Announces $5 Million Private Placement with OPKO Health (GlobeNewswire) +14.63%
Jun-03-26 07:00AM	Cocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, as Chief Executive Officer (GlobeNewswire)
May-26-26 08:00AM	Cocrystal Pharma Announces Discovery of Pan-Viral Inhibitors Targeting Hantavirus, Bunyavirus and Influenza (GlobeNewswire)
May-15-26 08:00AM	Cocrystal Pharma Provides Business Update and Reports First Quarter 2026 Financial Results (GlobeNewswire)
Apr-30-26 04:05PM	Cocrystal Pharma Presentation at ICAR 2026 Highlights Mechanism of Action and Clinical Advancement of CDI-988 for the Prevention and Treatment of Norovirus Infection (GlobeNewswire)
Apr-02-26 10:30AM	BC-Most Active Stocks (Associated Press) +48.04%
08:00AM	Cocrystal Pharma Receives FDA Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Preventive (GlobeNewswire)
Mar-31-26 08:00AM	Cocrystal Pharma Reports 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs (GlobeNewswire)
Mar-09-26 08:00AM	First Subjects Dosed in Cocrystal Pharma's Phase 1b Study Evaluating CDI-988 for Norovirus Prevention and Treatment (GlobeNewswire)
Feb-19-26 08:00AM	Cocrystal Pharma's First Oral Norovirus Protease Inhibitor CDI-988 to be Featured at the International Society for Antiviral Research Conference (ICAR) 2026 (GlobeNewswire)
08:00AM	Loading…
Dec-18-25 08:00AM	Cocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of Norovirus (GlobeNewswire)
Dec-01-25 08:00AM	Cocrystal Pharma to Present at the Noble Capital Markets' 21st Emerging Growth Equity Conference (GlobeNewswire)
Nov-14-25 08:00AM	Cocrystal Pharma Reports Third Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs (GlobeNewswire)
Oct-30-25 08:00AM	Cocrystal Pharma Insiders Purchase $1.03 Million in Private Placement Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
Oct-27-25 08:00AM	Cocrystal Pharma Receives NIH SBIR Award to Advance its Influenza Inhibitor Program (GlobeNewswire)
Oct-02-25 08:00AM	Cocrystal Pharma to Present at Noble Capital Markets Emerging Growth Virtual Equity Conference (GlobeNewswire)
Sep-15-25 04:30PM	Cocrystal Pharma, Inc. Announces Closing of Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) -9.49% -7.69%
Sep-12-25 09:43AM	Cocrystal Pharma, Inc. Announces Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) +9.72%
08:00AM	Cocrystal Pharma Showcases CDI-988, the First Oral Antiviral in Development for Norovirus Infection, in a Podium Presentation at the International Calicivirus Conference (GlobeNewswire)
Sep-08-25 08:00AM	Cocrystal Pharma Receives FDA IND Clearance for Challenge Study of Oral Broad-Spectrum Protease Inhibitor CDI-988, a Potential First Antiviral for Norovirus Prevention and Treatment (GlobeNewswire)
Sep-03-25 08:00AM	Cocrystal Pharma to Participate at the H.C. Wainwright Global Investment Conference (GlobeNewswire)
Aug-14-25 08:00AM	Cocrystal Pharma Reports Second Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs (GlobeNewswire)
Aug-05-25 08:00AM	Cocrystal Pharma Presents Phase 1 Results for Pan-Viral Inhibitor CDI-988 at Department of Defense Medical Conference (GlobeNewswire) -14.95%
Jul-10-25 08:00AM	Cocrystal Pharma to Present Data from Phase 1 Study of First-in-Class Norovirus Protease Inhibitor CDI-988 at the 9th International Calicivirus Conference (GlobeNewswire)
Jun-05-25 08:00AM	Cocrystal Pharma's Novel Norovirus Antiviral to be Presented at Department of Defense Medical Conference (GlobeNewswire)
08:00AM	Loading…
May-29-25 08:00AM	Cocrystal Pharma's Investigational Drug Candidate CC-42344 Demonstrates Strong Antiviral Potency Against the 2024 Highly Pathogenic H5N1 Avian Influenza Strain (GlobeNewswire) +8.74%
May-28-25 08:00AM	Cocrystal Pharma to Participate in Noble Capital Markets' 2025 Emerging Growth Virtual Equity Conference (GlobeNewswire)
May-15-25 08:00AM	Cocrystal Pharma Reports First Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs (GlobeNewswire)
Apr-24-25 08:00AM	Cocrystal Pharma's Norovirus Oral Antiviral Candidate Demonstrates Potent Activity Against the Emerging GII.17 Variants (GlobeNewswire)
Apr-16-25 08:00AM	Cocrystal Pharma to Present at Life Science Innovation Northwest 2025 Conference (GlobeNewswire)
Mar-31-25 08:00AM	Cocrystal Pharma Reports 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs (GlobeNewswire)
Mar-14-25 08:35AM	Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing (GlobeNewswire)
Mar-12-25 01:12PM	Life Sciences Investor Forum Agenda Announced for March 13th (GlobeNewswire)
Mar-06-25 08:00AM	Cocrystal Pharma to Participate in a Fireside Chat at the Zacks SCR Life Sciences Virtual Investor Forum on March 13, 2025 (GlobeNewswire)
Jan-08-25 08:00AM	Cocrystal Pharma Reports Phase 1 Results with Oral, Broad-Acting Antiviral Drug CDI-988 for Prophylaxis and Treatment of Norovirus, Coronaviruses and Other Viral Infections (GlobeNewswire) +6.50%
Jan-02-25 06:34AM	Cocrystal to extend enrolment in Phase IIa influenza inhibitor trial (Clinical Trials Arena) +14.85%
Dec-31-24 02:03PM	Cocrystal Pharma Shares Drop 35% Following Phase 2a Study Extension Announcement (GuruFocus.com) -37.85%
08:00AM	Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344 (GlobeNewswire)
Nov-13-24 08:00AM	Cocrystal Pharma Reports Third Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs (GlobeNewswire)
Oct-31-24 08:00AM	Cocrystal Pharma's Co-CEOs Highlight Pioneering Approach to Antiviral Drug Candidates Targeting Influenza and Coronaviruses as Fall Flu and COVID Season Begins (GlobeNewswire)
Sep-26-24 08:00AM	Cocrystal Pharma Advances Oral Pan-Viral Protease Inhibitor CDI-988 into Phase 1 Multiple-Ascending Dose Cohorts (GlobeNewswire)
Aug-19-24 04:05PM	Cocrystal Pharma to Highlight Near-term Clinical Milestones During Presentations at Two Upcoming Investment Conferences (GlobeNewswire) +15.38% -9.05%
Aug-15-24 03:00PM	CoCrystal Pharma to Present at August 20th Virtual Investor Summit Microcap Event (ACCESSWIRE)
Aug-14-24 08:00AM	Cocrystal Pharma Reports Second Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs (GlobeNewswire) -10.53%
Jul-18-24 08:00AM	Cocrystal Pharma Reports Favorable Results from Single-Ascending Dose Cohorts of Phase 1 Study with CDI-988, its Oral Pan-Viral Norovirus/Coronavirus Protease Inhibitor (GlobeNewswire)
Jun-20-24 08:00AM	New Broad-Spectrum Antiviral Currently in a Phase 2a Clinical Trial in Influenza A may be Effective Against the H5N1 Avian Influenza Strain Identified in Humans Exposed to Infected Dairy Cows (GlobeNewswire)
Jun-07-24 09:55AM	Cocrystal Pharma, Inc. (COCP) Now Trades Above Golden Cross: Time to Buy? (Zacks)
May-13-24 01:53PM	COCP Stock Earnings: Cocrystal Pharma Beats EPS for Q1 2024 (InvestorPlace)
08:00AM	Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs (GlobeNewswire)
May-01-24 08:00AM	Enrollment Completed in Phase 2a Study with Cocrystal Pharma's Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza (GlobeNewswire)
Mar-28-24 01:53PM	COCP Stock Earnings: Cocrystal Pharma Beats EPS for Q4 2023 (InvestorPlace) -6.67%
08:00AM	Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs (GlobeNewswire)
Mar-19-24 08:00AM	Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A (GlobeNewswire)
Mar-05-24 08:30AM	Cocrystal Pharma Discusses Antiviral Therapeutics' Clinical Development and 2024 Value Catalysts in New CEO Video Interview on Planet MicroCap (ACCESSWIRE)
Jan-04-24 08:00AM	Cocrystal Pharma Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investigational Candidates (GlobeNewswire)
Dec-06-23 08:00AM	Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A (GlobeNewswire)
Nov-29-23 08:00AM	Cocrystal Pharma Highlights its Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast (GlobeNewswire)
Nov-27-23 08:00AM	Cocrystal Pharma to Present at the NobleCon 19 Conference on December 4, 2023 (GlobeNewswire) +17.12%
Nov-13-23 08:00AM	Cocrystal Pharma Reports Third Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs (GlobeNewswire)
Nov-09-23 08:00AM	Cocrystal Pharma to Discuss Progress with Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast (GlobeNewswire)
Oct-31-23 08:00AM	Cocrystal Pharma Receives UK MHRA Authorization to Initiate Its Phase 2a Influenza Human Challenge Trial with Oral PB2 Inhibitor CC-42344 (GlobeNewswire) +5.25%
Oct-02-23 12:14PM	COCP: Cocrystal Pharma doses 1st subjects in the important CDI-988 clinical trial. (Zacks)
Sep-28-23 08:00AM	Cocrystal Pharma Doses First Subjects in Clinical Study of CDI-988 For Pandemic Norovirus and Coronavirus (GlobeNewswire)
Sep-05-23 08:00AM	Cocrystal Pharma to Participate in the H.C. Wainwright Global Investment Conference (GlobeNewswire) -8.38%
Aug-16-23 09:11AM	COCP: Cocrystal Pharma reports 2nd quarter 2023 financial results and provides updates on drug pipeline. (Zacks)
Aug-14-23 08:00AM	Cocrystal Pharma Reports Second Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs (GlobeNewswire)
Aug-08-23 08:00AM	Cocrystal Pharma Selects Novel Oral Protease Inhibitor CDI-988 as Norovirus Lead (GlobeNewswire) +7.39%
May-31-23 08:00AM	Cocrystal Pharma Receives HREC Approval to Initiate Phase 1 Study to Evaluate Oral Broad-Spectrum Coronavirus 3CL Protease Inhibitor CDI-988 (GlobeNewswire)
May-17-23 09:26AM	COCP: Cocrystal Pharma reports 1st quarter 2023 financial results and provides updates on drug pipeline. (Zacks Small Cap Research) -5.88%
May-15-23 08:00AM	Cocrystal Pharma Reports First Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs (GlobeNewswire) -5.28%
May-04-23 04:05PM	Cocrystal Pharma Presents New Data from its CC-42344 Phase 1 Influenza A Study at the 7th Annual ISIRV Antiviral Group Conference (GlobeNewswire)
Apr-24-23 08:00AM	Cocrystal Pharma Appoints Pharma Industry Veteran Fred Hassan to its Board of Directors (GlobeNewswire) +6.05%
Apr-18-23 08:00AM	Cocrystal Pharma to Present New Data from its CC-42344 Phase 1 Influenza A Study at the 7th Annual ISIRV Antiviral Group Conference (GlobeNewswire)
Apr-10-23 08:30AM	Cocrystal Pharma Completes $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) +12.95%
Mar-31-23 10:05AM	COCP: UPDATE: Cocrystal Pharma announces full year 2022 financial results and provides drug program updates. (Zacks Small Cap Research) +5.85%
Mar-29-23 08:00AM	Cocrystal Pharma Reports 2022 Financial Results and Provides Updates on its Antiviral Drug Development Programs (GlobeNewswire)
Mar-22-23 01:03PM	COCP: UPDATE: Cocrystal Pharma announced several program updates and investor events. (Zacks Small Cap Research)
08:00AM	Cocrystal Pharma to Highlights Progress with Its Antiviral Portfolio at the Virtual Investor Summit on March 29, 2023 (GlobeNewswire)
Jan-26-23 08:00AM	Cocrystal Pharma Announces Participation in Virtual Investor Events (GlobeNewswire) -6.62%
Jan-23-23 09:00AM	Cocrystal Pharma Discusses Clinical Progress and Significance of Its Novel Antiviral Therapeutics Pipeline with The Stock Day Podcast (Newsfile)
Dec-19-22 08:00AM	Cocrystal Pharma Reports Highly Favorable Safety and Tolerability Results from a Phase 1 Study with its Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A (GlobeNewswire) -11.39%
Dec-01-22 04:05PM	Cocrystal Pharma Highlights Progress with CC-42344 as a Potential Oral Treatment for Pandemic and Seasonal Influenza A at the World Antiviral Congress 2022 (GlobeNewswire)
Nov-17-22 01:38PM	Cocrystal Pharma Posts Favorable Safety Data From Oral Antiviral Against Influenza A (Benzinga)
08:00AM	Cocrystal Pharma Announces Favorable Safety Data from the Phase 1 Study with Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A (GlobeNewswire)
Nov-15-22 11:19AM	COCP: UPDATE: Cocrystal Pharma releases 2022 3rd quarter results and provides an update on the current pipeline programs. (Zacks Small Cap Research)
Nov-14-22 08:00AM	Cocrystal Pharma Reports Third Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs (GlobeNewswire)
Nov-02-22 08:00AM	Cocrystal Pharma to Participate in Two Investor Conferences in November (GlobeNewswire) +13.41%
Nov-01-22 04:05PM	Cocrystal Pharma Granted European Patent Covering Oral Antiviral Candidate CC-42344 in Combination with Another Antiviral Agent for the Treatment of Influenza (GlobeNewswire)
Oct-26-22 08:00AM	Enrollment Completed in Phase 1 Influenza A Study with Cocrystal Pharmas Oral Antiviral Candidate CC-42344 (GlobeNewswire)
Oct-19-22 08:00AM	Cocrystal Pharma to Present at the LD Micro Main Event XV (GlobeNewswire)
Oct-13-22 08:00AM	Cocrystal Pharma to Present CC-42344 Phase 1 Influenza A Data at the World Antiviral Congress 2022 (GlobeNewswire)
Oct-11-22 11:51AM	Cocrystal Pharma Advances One Of Its COVID-19 Antiviral Treatment Candidate (Benzinga) -9.02%
08:00AM	Cocrystal Pharma Selects CDI-988 for Clinical Development as an Oral Treatment for COVID-19 (GlobeNewswire)
Oct-05-22 08:00AM	Cocrystal Pharma to Present at the Dawson James Securities 2022 Small Cap Growth Conference (GlobeNewswire)
Oct-03-22 04:05PM	Cocrystal Pharma Announces a 1-for-12 Reverse Stock Split (GlobeNewswire) -13.65%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
FROST PHILLIP MD ET AL	Director	Aug 05 '26	Buy	0.98	10,000	9,816	1,993,551	Aug 06 05:11 PM
FROST PHILLIP MD ET AL	Director	Aug 03 '26	Buy	0.94	75,000	70,590	1,983,551	Aug 05 04:10 PM
FROST PHILLIP MD ET AL	Director	Feb 24 '26	Buy	1.00	20,000	19,952	1,908,551	Feb 25 04:10 PM
FROST PHILLIP MD ET AL	Director	Feb 06 '26	Buy	0.95	50,000	47,280	1,888,551	Feb 09 04:10 PM
FROST PHILLIP MD ET AL	Director	Dec 31 '25	Buy	0.95	50,000	47,275	1,838,551	Jan 02 04:10 PM
FROST PHILLIP MD ET AL	Director	Dec 30 '25	Buy	0.97	20,000	19,310	1,788,551	Dec 31 04:10 PM
FROST PHILLIP MD ET AL	Director	Dec 26 '25	Buy	0.97	40,000	38,944	1,768,551	Dec 29 09:24 AM
FROST PHILLIP MD ET AL	Director	Dec 24 '25	Buy	0.97	25,000	24,258	1,728,551	Dec 29 09:24 AM
FROST PHILLIP MD ET AL	Director	Nov 26 '25	Buy	0.99	4,000	3,975	1,703,551	Nov 28 09:00 AM
FROST PHILLIP MD ET AL	Director	Nov 25 '25	Buy	0.94	20,000	18,812	1,699,551	Nov 25 08:17 PM

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), noroviruses and hepatitis C viruses. Cocrystal employs unique structure-based technologies to create first- and best-in-class antiviral drugs. The company was founded in 2008 and is headquartered in Bothell, WA.

Co-FounderProf. Roger D. Kornberg Ph.D.

Chief Scientific OfficerDr. Sam Lee Ph.D.

M.B.A.Mr. James J. Martin CPA

R.Ph.Mr. James R. Sapirstein M.B.A.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

All the Features.Half the Price.

COCP

Cocrystal Pharma Inc

Upgrade your Finviz experience

All the Features.
Half the Price.